$150.25 Million in Sales Expected for Ionis Pharmaceuticals Inc (NASDAQ:IONS) This Quarter

Analysts expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to report sales of $150.25 million for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Ionis Pharmaceuticals’ earnings, with estimates ranging from $133.80 million to $181.50 million. Ionis Pharmaceuticals reported sales of $145.40 million in the same quarter last year, which indicates a positive year over year growth rate of 3.3%. The company is expected to report its next earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that Ionis Pharmaceuticals will report full-year sales of $798.18 million for the current year, with estimates ranging from $738.15 million to $934.00 million. For the next financial year, analysts expect that the firm will report sales of $951.62 million, with estimates ranging from $641.54 million to $1.81 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.26. Ionis Pharmaceuticals had a net margin of 49.90% and a return on equity of 38.70%. The firm had revenue of $164.00 million during the quarter, compared to the consensus estimate of $145.31 million. During the same period in the previous year, the firm posted ($0.29) earnings per share. The business’s revenue was up 39.0% compared to the same quarter last year.

Several equities research analysts have recently commented on IONS shares. BidaskClub raised shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. Sanford C. Bernstein raised shares of Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research report on Tuesday, September 10th. BMO Capital Markets decreased their target price on shares of Ionis Pharmaceuticals from $96.00 to $95.00 and set an “outperform” rating for the company in a research report on Wednesday, July 24th. Wells Fargo & Co boosted their target price on shares of Ionis Pharmaceuticals from $90.00 to $120.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, ValuEngine downgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $75.40.

Shares of NASDAQ:IONS traded up $0.64 during midday trading on Friday, hitting $62.74. 810,264 shares of the company’s stock were exchanged, compared to its average volume of 986,185. The company has a debt-to-equity ratio of 0.45, a current ratio of 10.01 and a quick ratio of 9.93. The stock has a 50 day moving average price of $62.64 and a 200-day moving average price of $67.89. The company has a market cap of $8.25 billion, a PE ratio of 21.20 and a beta of 1.95. Ionis Pharmaceuticals has a 12 month low of $43.27 and a 12 month high of $86.58.

In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 22,000 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $71.52, for a total value of $1,573,440.00. Following the completion of the sale, the chairman now directly owns 79,634 shares of the company’s stock, valued at approximately $5,695,423.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Stanley T. Crooke sold 10,000 shares of the company’s stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $70.25, for a total transaction of $702,500.00. Following the completion of the sale, the chief executive officer now directly owns 79,634 shares of the company’s stock, valued at $5,594,288.50. The disclosure for this sale can be found here. Corporate insiders own 2.40% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IONS. Whittier Trust Co. boosted its stake in Ionis Pharmaceuticals by 283.0% in the second quarter. Whittier Trust Co. now owns 383 shares of the company’s stock valued at $25,000 after acquiring an additional 283 shares during the last quarter. CWM LLC boosted its stake in Ionis Pharmaceuticals by 361.4% in the second quarter. CWM LLC now owns 406 shares of the company’s stock valued at $26,000 after acquiring an additional 318 shares during the last quarter. Ellis Investment Partners LLC purchased a new position in Ionis Pharmaceuticals in the second quarter valued at about $32,000. Rehmann Capital Advisory Group boosted its stake in Ionis Pharmaceuticals by 41.3% in the second quarter. Rehmann Capital Advisory Group now owns 592 shares of the company’s stock valued at $38,000 after acquiring an additional 173 shares during the last quarter. Finally, Advisory Services Network LLC boosted its stake in Ionis Pharmaceuticals by 38.5% in the second quarter. Advisory Services Network LLC now owns 907 shares of the company’s stock valued at $58,000 after acquiring an additional 252 shares during the last quarter. Hedge funds and other institutional investors own 89.05% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Recommended Story: What are gap-up stocks?

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.